Form 4: CONMED Director Brian Concannon Reports New Equity Grants and RSU Conversion

CONMED Corporation Director Brian Concannon has reported the acquisition of new stock options and restricted stock units (RSUs), alongside the conversion of previously granted RSUs into common stock.

Summary

• Brian Concannon, a Director at CONMED Corp (CNMD), reported changes in his beneficial ownership of company securities.
• On June 2, 2025, Mr. Concannon was granted 8,061 stock options with an exercise price of $55.38 per share, vesting 100% after one year (June 2, 2026) and expiring on June 2, 2035, under the Company's 2025 Long-Term Incentive Plan.
• Also on June 2, 2025, Mr. Concannon acquired 668 Restricted Stock Units (RSUs), which represent a contingent right to receive one share of common stock, vesting 100% after one year (June 2, 2026) and immediately upon termination of Director's service, expiring on June 2, 2035, under the 2025 Long-Term Incentive Plan.
• On June 3, 2025, 479 Restricted Stock Units (RSUs) were converted into common stock, reducing the RSU balance to zero for that specific grant, which was originally granted under the 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.
• Following these transactions, Mr. Concannon directly beneficially owns 10,116 shares of Common Stock, 8,061 stock options, and 668 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation grants to a director, which is generally viewed positively as it aligns the director's financial interests with the company's long-term performance and shareholder value.

Positives

• The grant of new stock options and restricted stock units to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The equity compensation plans (2025 Long-Term Incentive Plan and 2020 Amended and Restated Non-Employee Director Equity Compensation Plan) are in place, indicating a structured approach to executive and director compensation.

Future Outlook

The document primarily details past and current equity transactions and does not provide specific forward-looking financial guidance or business outlook beyond the vesting schedules of the granted equity.

Industry Context

The granting of stock options and restricted stock units to directors is a common practice in publicly traded companies across various industries, including medical technology, to align the interests of directors with long-term shareholder value creation.

Corporate Governance

Related Party Transactions

• The acquisition of stock options and restricted stock units, and the conversion of RSUs into common stock by Director Brian Concannon, constitute related party transactions as they involve compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions aimed at increasing shareholder value.

Next Steps

• The newly granted stock options and restricted stock units are scheduled to vest on June 2, 2026, subject to the terms of the respective incentive plans and continued service.

Key Dates

Keywords

CONMED Corp, CNMD, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership